Director, Center for Evolution and Cancer, UCSF; Adjunct Associate Professor, Surgery, UCSF; Associate Professor, School of Life Sciences, Arizona State University
I specialize in the evolutionary analysis of neoplasms, both for understanding progression to malignancy and the response to therapy. Most of my work has been in Barrett’s Esophagus and acute myeloid leukemia (AML), though I am interested in all cancers. We have shown that measures of intra-tumor genetic heterogeneity predict progression to malignancy in Barrett’s esophagus. We predict that the degree of heterogeneity should also correlate with the presence of a resistant clone, and so predict time until relapse after therapy. We are developing phylogenetic methods to measure the dynamics in tumors including mutation rates, clonal expansions, stem cell population sizes and time since initiation. We are interested in whole genome sequencing and epigenetic profiling of pre-malignant and malignant neoplasms, particularly in cases where they can be tracked over time. We are currently usinging the techniques to study the impact of non-steroidal anti-inflammatory drugs (NSAIDs) on clonal evolution in Barrett’s Esophagus.
Oberlin College, Oberlin, OH B.A., 1991, Computer Science/Psychology
Oxford University, Oxford, UK, M.S., 1993, Zoology
MIT, Cambridge, MA, Ph.D., 1998, Computer Science
Harvard University, Cambridge, MA, Postdoc, 1998, Evolutionary Biology
University of New Mexico, Albuquerque, NM Postdoc, 1998-2000, Computational Biology